RxDoctor Payments Data

Robert Leininger, MD

Infectious Disease · Canton, OHNPI 1902068059

Payments from drug & device makers

$5,315in general payments, 2019–2025

Across 284 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$726
  • Merck$702
  • AbbVie$576
  • Johnson & Johnson$415
  • Melinta Therapeutics, LLC$400
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$5,21498%
  • Education$1012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,315 in reported general payments places this provider in the 75th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$77,157
Medicare patients
271
Services billed
785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala159$747,491
TivicayDolutegravir Sodium36$120,933
OdefseyEmtricitab/Rilpiviri/Tenof Ala24$85,675
TriumeqAbacavir/Dolutegravir/Lamivudi16$58,720
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$43,091
DovatoDolutegravir Sodium/Lamivudine13$38,125
Cefepime Hcl61$19,594
Vancomycin Hcl94$16,066
VemlidyTenofovir Alafenamide11$15,602
AbacavirAbacavir Sulfate16$8,928
Abacavir-LamivudineAbacavir Sulfate/Lamivudine11$7,868
Meropenem28$6,285
ErtapenemErtapenem Sodium25$5,799
CeftriaxoneCeftriaxone Sodium51$5,143
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam29$4,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Vemlidy$1,322$806,185181 claims
Viiv Healthcare CompanyTivicay, Triumeq, Dovato$726$217,77865 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →